• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by BGM Group Ltd.

    3/28/25 4:30:58 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGM alert in real time by email
    6-K 1 tm2510779d1_6k.htm FORM 6-K

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2025

     

    BGM Group Ltd

     

    No. 152 Hongliang East 1st Street, No. 1703,

    Tianfu New District, Chengdu, 610200

    People’s Republic of China

    +86-028-64775180

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x Form 40-F ¨

     

     

     

     

     

     

    Financial Information Regarding Acquisition with Patriton Limited

     

    References are made to the Current Report on Form 6-K filed by BGM Group Ltd (the “Company”) on January 7, 2025 and November 29, 2024 (the “Prior 6-K”). In connection with the signing of the Transaction Agreement dated November 27, 2024 (the “Agreement”) by and among the Company, CISG Holdings Ltd (the “Seller”), Patriton Limited (the “Target Company”), GM Management Company Limited, DuXiaoBao Intelligent Technology (Shenzhen) Co., Ltd., RONS Intelligent Technology (Beijing) Co., Ltd., Shenzhen Xinbao Investment Management Co., Ltd., Fanhua RONS Insurance Sales & Service Co., Ltd. and Shenzhen Baowang E-commerce Co., Ltd., the Company agreed to purchase from the Seller, 100% of the equity interest of the Target Company, for a consideration of 69,995,661 Class A ordinary shares with a par value of US$0.00833335 per share of the Company (the “Consideration Shares”), at a purchase price of US$2.0 per share of the Consideration Shares, and the closing took place on January 7, 2025, as disclosed in the Prior 6-K.

     

    In compliance with the Rule 3-05 of Regulation S-X, the Company is filing this Current Report on Form 6-K to submit (i) the audited financial statements of Rons Intelligent Technology (Beijing) Co., Ltd. and Shenzhen Xinbao Investment Management Co., Ltd. for the years ended September 30, 2024 and 2023 filed herewith as Exhibit 99.1; and 2) the unaudited pro forma consolidated combined financial statements as of September 30, 2024 of the Company and its subsidiaries filed herewith as Exhibit 99.2 upon giving effect to the consummation of the acquisition of Patriton Limited.

     

    The unaudited pro forma consolidated combined financial information that has been included as Exhibit 99.2 to this Current Report on Form 6-K does not necessarily reflect what the Company’s results of operations, balance sheets or cash flows would have been during the periods presented had the Acquisition been completed in prior periods and does not necessarily indicate what the Company’s results of operations, balance sheets, cash flows or costs and expenses will be in the future.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    99.1   Audited financial statements of Rons Intelligent Technology (Beijing) Co., Ltd. and Shenzhen Xinbao Investment Management Co., Ltd. for the years ended September 30, 2024 and 2023
    99.2   Unaudited pro forma consolidated combined financial statements as of September 30, 2024 of the Company and its subsidiaries

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: March 28, 2025

     

      BGM Group Ltd
         
      By: /s/ Chen Xin
      Name:  Chen Xin
      Title: Chief Executive Officer

     

     

     

     

    Get the next $BGM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BGM Group Announces Strategic Acquisition of HM Management to Expand AI Application Ecosystem

      CHENGDU, China, May 2, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) (the "Company" or "BGM") , a leading AI technology company, today announced it has entered into a definitive agreement (the "Agreement") to acquire HM Management Company Limited ("HM Management"), a prominent AI agent production platform, in an all-stock transaction valued at approximately RMB300 million (US$41.7 million). Under the Agreement, BGM will issue 16,663,427 Class A ordinary shares at $2.50 per share to acquire 100% ownership of HM Management and its two wholly-owned subsidiaries: Beijing Shuda Technology Company Limited. ("Shuda Technology") and New Media Star Technology (Shenzhen) Co., Ltd ( "New Media Star

      5/2/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Completes Acquisition of YX to Advance AI-Powered Intelligent Platform

      CHENGDU, China, April 28, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) (the "Company" or BGM)  today announced the completion of its acquisition of YX Management Company Ltd. ("YX"), an leading intelligent mobility technology platform, on April 25, 2025. As previously disclosed, BGM acquired 100% of YX by issuing 47.5 million Class A ordinary shares to YX's existing shareholders, representing a valuation of US$95.0 million. Upon completion of the acquisition, YX's shareholders collectively own approximately 32.6% of BGM's equity interests and approximately 2.2% of the total voting power. This acquisition represents a significant step in BGM's AI-driven transformation, enhancing its capa

      4/28/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy

      CHENGDU, China, April 21, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ("Wonder Dragon"), to acquire 100% of the equity interests of Wonder Dragon by issuing 38,165,290 Class A ordinary shares at a price of $2 per share, for a total transaction valuation of RMB550 million. The transaction is expected to be completed in the second quarter of 2025. Wonder Dragon possesses over 3,000 metric tons of premium Qingzhuan dark tea inventory, comprising 1,670 metric tons of raw materials and 1,350 metric tons of finished products. These premium tea products, known f

      4/21/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGM
    SEC Filings

    See more
    • Amendment: SEC Form 20-F/A filed by BGM Group Ltd.

      20-F/A - BGM Group Ltd. (0001779578) (Filer)

      5/8/25 8:04:36 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by BGM Group Ltd.

      6-K - BGM Group Ltd. (0001779578) (Filer)

      5/6/25 9:06:17 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by BGM Group Ltd.

      6-K - BGM Group Ltd. (0001779578) (Filer)

      4/28/25 7:54:10 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGM
    Leadership Updates

    Live Leadership Updates

    See more
    • BGM Group Announces Board Reshuffle: New Leadership Embarks on a Transformative Journey Amid Tech Revolution

      CHENGDU, China, Feb. 28, 2025 /PRNewswire/ -- BGM Group Ltd (NASDAQ:BGM) (the "Company" or "BGM") today announced changes to its board of directors, marking the Company's entry into a new phase of technological transformation and sustainable growth. Mr. Zhanchang Xin has tendered his resignation and will step down from his role as Chairman of the Company, effective March 1, 2025. He will be succeeded by Mr. Chen Xin, the current Chief Executive Officer of the Company, who will assume the position of Chairman. As the founder of the Company, Mr. Zhanchang Xin has, over the past six decades, has played a pivotal role in leading the Company through numerous challenges and milestones, including

      2/28/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Group Establishes "Duxiaobao Management Committee" to Accelerate AI Strategy and Drive Intelligent Transformation in the Insurance Industry

      CHENGDU, China, Feb. 19, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) announced the establishment of the "Duxiaobao Management Committee," which will be fully responsible for the management and decision-making of the "Duxiaobao" ecosystem. This move signifies BGM Group's strategic entry into the field of artificial intelligence, aiming to accelerate the transformation of the insurance industry into the smart era through AI technology. The Duxiaobao Management Committee consists of industry leaders such as Xin Chen, Li Yuqing, Ge Peng, Zhao Qi, Ren Yong, Li Jun, Zhou Xin, and Wang Hui. The committee has appointed Li Yuqing as the CEO of Duxiaobao, with Li Jun, Ren Yong, Zhou Xin, and Tan

      2/19/25 7:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGM
    Financials

    Live finance-specific insights

    See more
    • BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy

      CHENGDU, China, April 21, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ("Wonder Dragon"), to acquire 100% of the equity interests of Wonder Dragon by issuing 38,165,290 Class A ordinary shares at a price of $2 per share, for a total transaction valuation of RMB550 million. The transaction is expected to be completed in the second quarter of 2025. Wonder Dragon possesses over 3,000 metric tons of premium Qingzhuan dark tea inventory, comprising 1,670 metric tons of raw materials and 1,350 metric tons of finished products. These premium tea products, known f

      4/21/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Acquires YX to Strengthen AI Strategy for Its Intelligent Platform

      CHENGDU, China, March 19, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM) (NASDAQ:BGM) today announced that it has signed a definitive agreement with the existing shareholders of YX Management Company Ltd. ("YX"), a smart mobility technology company. Under the agreement, BGM will acquire 100% of the equity interests of YX by issuing 47.5 million class A ordinary shares to its existing shareholders, valuing YX at US$95.0 million. This acquisition is based on the exceptional expertise and experience of the YX team in scalable operations, digital infrastructure development, and technology commercialization. The integration of this team will accelerate the AI-driven strategic upgrade

      3/19/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by BGM Group Ltd.

      SC 13D - BGM Group Ltd. (0001779578) (Subject)

      12/3/24 6:03:06 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BGM Group Ltd.

      SC 13D/A - BGM Group Ltd. (0001779578) (Subject)

      11/29/24 9:00:27 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Qilian International Holding Group Ltd.

      SC 13D - Qilian International Holding Group Ltd (0001779578) (Subject)

      10/16/24 4:19:46 PM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care